Aptose Biosciences Inc. (APTOF) intrinsic value & 10-year financials
Aptose Biosciences Inc. (APTOF) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue reached to $0, with an average return on invested capital of -39.2%.
- Graham intrinsic value
- —
- Revenue (FY2025)
- $0
- ROIC (10-yr avg)
- -39.2%
- Free cash flow (FY2025)
- -$22.0M
APTOF 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$25.5M | -$10.41 | -$22.0M | — | 131.9% |
| FY2024 | $0 | -$25.4M | -$36.38 | -$36.0M | — | 230.8% |
| FY2023 | $0 | -$51.2M | -$7.58 | -$44.6M | — | 1049.4% |
| FY2022 | $0 | -$41.8M | -$0.01 | -$32.3M | — | -226.0% |
| FY2021 | $0 | -$65.4M | -$0.01 | -$43.5M | — | -350.5% |
| FY2020 | $0 | -$55.2M | — | -$34.0M | — | -644.1% |
| FY2019 | — | -$26.3M | — | -$21.7M | — | -174.1% |
| FY2018 | — | -$28.9M | — | -$23.5M | — | -237.8% |
| FY2017 | — | -$11.6M | — | -$10.2M | — | -132.8% |
| FY2016 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Aptose Biosciences Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Aptose Biosciences Inc. has historically struggled to out-earn its cost of capital, averaging just -0.5% ROIC.
Aptose Biosciences Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Aptose Biosciences Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.